维多珠单抗治疗两种不同的抗肿瘤坏死因子α难治性袋状结肠炎的有效性：一例报告。
Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report.
作者信息
Cakir Ozlem Ozer
机构信息
Department of Gastroenterology and Hepatology, Alanya Alaaddin Keykubat University, School of Medicine, Antalya 07425, Turkey.
出版信息
World J Clin Cases. 2019 Aug 26;7(16):2316-2321. doi: 10.12998/wjcc.v7.i16.2316.
BACKGROUND
Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of vedolizumab on treatment of the patient with refractory pouchitis.
CASE SUMMARY
A 32-year-old male with pancolonic ulcerative colitis since the age of 25 with primary failure of infliximab and mesalamine and intolerance of azathioprine, underwent a total proctocolectomy with ileal pouch-anal anastomosis in 2012. He developed chronic diarrhea in 2014, which was watery, 30 per day and accompanied with blood and mucus affecting his quality of life.
CONCLUSION
Vedolizumab is safe and effective in the management of anti-tumor necrosis factor alpha refractory pouchitis.
背景
难治性袋炎是袋状结构功能衰竭的常见原因，可能需要手术切除袋状结构或永久性造口。我们旨在展示维多珠单抗对难治性袋炎患者的治疗效果。
病例摘要
一名32岁男性，自25岁起患有全结肠溃疡性结肠炎，英夫利昔单抗和美沙拉嗪初治失败，且对硫唑嘌呤不耐受，于2012年接受了全直肠结肠切除术及回肠袋肛管吻合术。2014年他出现慢性腹泻，呈水样便，每天30次，并伴有血便和黏液便，影响其生活质量。
结论
维多珠单抗在治疗抗肿瘤坏死因子α难治性袋炎方面安全有效。
Zotero 插件